MX2021014116A - Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents
Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).Info
- Publication number
- MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- purinoreceptor
- inhibitors
- pyrido
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177610 | 2019-05-31 | ||
| EP19201165 | 2019-10-02 | ||
| PCT/EP2020/064915 WO2020239953A1 (en) | 2019-05-31 | 2020-05-28 | Pyridopyrimidines derivatives as p2x3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014116A true MX2021014116A (es) | 2021-12-10 |
Family
ID=70857198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014116A MX2021014116A (es) | 2019-05-31 | 2020-05-28 | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606562B2 (https=) |
| EP (1) | EP3976609A1 (https=) |
| JP (1) | JP7797204B2 (https=) |
| KR (1) | KR102923602B1 (https=) |
| CN (1) | CN114222741B (https=) |
| AU (1) | AU2020281924B2 (https=) |
| BR (1) | BR112021020279A2 (https=) |
| CA (1) | CA3136024A1 (https=) |
| MA (1) | MA56020A (https=) |
| MX (1) | MX2021014116A (https=) |
| WO (1) | WO2020239953A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139018A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| JP7797204B2 (ja) | 2019-05-31 | 2026-01-13 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体 |
| WO2022160931A1 (zh) * | 2021-01-28 | 2022-08-04 | 浙江海正药业股份有限公司 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
| AR132737A1 (es) | 2023-05-22 | 2025-07-23 | Chiesi Farm Spa | Proceso e intermedios para la preparación de un inhibidor p2x3 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH31122A (en) | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| JP4342007B2 (ja) * | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| CA2557372C (en) | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| CN101300012B (zh) * | 2005-09-01 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用 |
| MX2008014689A (es) | 2006-05-23 | 2008-11-27 | Hoffmann La Roche | Derivados de piridopirimidininona. |
| EP2038264B1 (en) | 2006-06-29 | 2016-10-26 | F.Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
| TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| EP2136639B1 (en) | 2007-04-02 | 2016-03-09 | Evotec AG | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| PT2139334E (pt) | 2007-04-17 | 2013-10-02 | Evotec Ag | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos |
| CA2715835C (en) | 2008-02-29 | 2017-03-21 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| BRPI0919488A2 (pt) | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
| PL2399910T3 (pl) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| KR101685862B1 (ko) | 2012-12-27 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | Comt 억제제 |
| WO2016053794A1 (en) | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| JPWO2016084922A1 (ja) | 2014-11-28 | 2017-09-07 | 塩野義製薬株式会社 | １，２，４−トリアジン誘導体およびその医薬組成物 |
| WO2016088838A1 (ja) | 2014-12-04 | 2016-06-09 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
| EP3230281B1 (en) | 2014-12-09 | 2021-05-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| DK3355889T3 (da) | 2015-09-29 | 2023-05-15 | Afferent Pharmaceuticals Inc | Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste |
| JP6882289B2 (ja) * | 2015-11-25 | 2021-06-02 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | 二環式ｂｅｔブロモドメイン阻害剤及びその使用 |
| CN106565684B (zh) | 2016-03-18 | 2019-06-18 | 南方医科大学 | 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用 |
| CA3029457A1 (en) | 2016-06-30 | 2018-01-04 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| US11000491B2 (en) | 2017-05-05 | 2021-05-11 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| RS63661B1 (sr) * | 2018-07-25 | 2022-11-30 | Faes Farma Sa | Piridopirimidini kao inhibitori histaminskog h4-receptora |
| CN109721554A (zh) | 2019-01-08 | 2019-05-07 | 贵州大学 | 一类4-氨基喹唑啉类化合物及其制备方法和应用 |
| JP7797204B2 (ja) | 2019-05-31 | 2026-01-13 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体 |
| CA3139018A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
-
2020
- 2020-05-28 JP JP2021571021A patent/JP7797204B2/ja active Active
- 2020-05-28 CA CA3136024A patent/CA3136024A1/en active Pending
- 2020-05-28 WO PCT/EP2020/064915 patent/WO2020239953A1/en not_active Ceased
- 2020-05-28 BR BR112021020279A patent/BR112021020279A2/pt unknown
- 2020-05-28 US US17/615,012 patent/US12606562B2/en active Active
- 2020-05-28 MX MX2021014116A patent/MX2021014116A/es unknown
- 2020-05-28 CN CN202080038831.1A patent/CN114222741B/zh active Active
- 2020-05-28 AU AU2020281924A patent/AU2020281924B2/en active Active
- 2020-05-28 KR KR1020217038473A patent/KR102923602B1/ko active Active
- 2020-05-28 MA MA056020A patent/MA56020A/fr unknown
- 2020-05-28 EP EP20728500.8A patent/EP3976609A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022534434A (ja) | 2022-07-29 |
| JP7797204B2 (ja) | 2026-01-13 |
| WO2020239953A1 (en) | 2020-12-03 |
| US20230212169A9 (en) | 2023-07-06 |
| US20220235060A1 (en) | 2022-07-28 |
| CN114222741A (zh) | 2022-03-22 |
| KR20220016074A (ko) | 2022-02-08 |
| US12606562B2 (en) | 2026-04-21 |
| MA56020A (fr) | 2022-04-06 |
| AU2020281924A1 (en) | 2021-12-16 |
| CA3136024A1 (en) | 2020-12-03 |
| AU2020281924B2 (en) | 2026-04-16 |
| EP3976609A1 (en) | 2022-04-06 |
| KR102923602B1 (ko) | 2026-02-06 |
| BR112021020279A2 (pt) | 2021-12-14 |
| CN114222741B (zh) | 2025-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017031A2 (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3) | |
| MX2021014116A (es) | Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). | |
| MX393050B (es) | Derivados de amida de tirosina como inhibidores de rho-cinasa. | |
| ECSP21004787A (es) | Inhibidores de inflamasoma nlrp3 | |
| CR20160327A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CL2020002939A1 (es) | Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| BR112015009486A2 (pt) | surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído | |
| EA201590030A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент | |
| CR20140516A (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| UY32938A (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| BR112023004612A2 (pt) | Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-acetamida como inibidores de receptor i de fator-beta de crescimento transformador/alk5 | |
| MX2023005801A (es) | Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3). | |
| MX2023005803A (es) | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2023005865A (es) | Derivados de dihidrofuropiridina como inhibidores de rho-cinasa. | |
| EA202193300A1 (ru) | Производные аминохиназолина в качестве p2x3 ингибиторов | |
| CO2023009444A2 (es) | Derivados de dihidrofuropiridina como inhibidores de la rho-cinasa | |
| MX377199B (es) | Nuevo compuesto aislado a partir de pseudolysimachion rotundum var. subintegrum que contiene cantidades abundantes del ingrediente activo, la composicion que lo comprende para prevenir o tratar la enfermedad alergica, enfermedad inflamatoria, asma o enfermedad pulmonar obstructiva cronica y el uso del mismo. | |
| UY38550A (es) | Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados | |
| PH12022550895A1 (en) | Compositions for preventing or treating chronic obstructive pulmonary diseases (copd) |